Develops immunotherapy treatments for cancer, focusing on targeted therapy for advanced breast cancer.
BriaCell Therapeutics Corp. is a biotechnology company specializing in immuno-oncology, dedicated to advancing innovative immunotherapies for cancer treatment. Central to its portfolio is Bria-IMT, a promising whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials. This vaccine is being investigated in combination with the novel immunotherapy agent retifanlimab, aiming to enhance treatment outcomes for cancer patients.
In addition to Bria-IMT, the company is developing Bria-OTS, an off-the-shelf personalized immunotherapy designed specifically for advanced breast cancer. BriaDx, another significant development, is a diagnostic test tailored to identify patients' HLA types, aiding in personalized treatment approaches. BriaCell Therapeutics Corp. collaborates extensively with partners in the field, including a non-exclusive clinical trial collaboration with Incyte Corporation to explore novel therapeutic combinations.
Headquartered in West Vancouver, Canada, BriaCell Therapeutics Corp. operates with a commitment to innovation and patient-focused research. The company also holds a cooperative research and development agreement with the National Cancer Institute, underscoring its dedication to advancing cancer therapies through rigorous preclinical studies and clinical trials. With its robust pipeline and strategic collaborations, c,BriaCell Therapeutics Corp. aims to make significant strides in improving cancer treatment outcomes globally.